Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-(6-fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)-4-phenylpiperidine-4-carbonitrile
i.e. NCT-505
-
2,3,5,6,9-pentamethyl-7H-furo[3,2-g][1]benzopyran-7-one
21.6% inhibition at 0.01 mM
-
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
9.5% inhibition at 0.01 mM
-
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
63.7% inhibition at 0.01 mM
-
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
91.3% inhibition at 0.01 mM
-
2,3-dimethyl-5-propyl-7H-furo[3,2-g][1]benzopyran-7-one
25.9% inhibition at 0.01 mM
-
2-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
16.79% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
14.47% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
29.37% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
8.5% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]-N-phenylacetamide
50.4% inhibition at 0.01 mM
-
2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetamide
71.5% inhibition at 0.01 mM
-
2H-furo[2,3-h][1]benzopyran-2-one
39.0% inhibition at 0.01 mM
-
3,3',5-tri-iodothyronine
-
3,3',5-Triiodothyroacetic acid
-
0.001 mM, 60% inhibition
3,4,10-trimethyl-2H,6H-benzo[1,2-b:5,4-b']dipyran-2,6-dione
32.6% inhibition at 0.01 mM
-
3,4,8,9-tetramethyl-7H-furo[2,3-f][1]benzopyran-7-one
38.5% inhibition at 0.01 mM
-
3,4-dimethyl-6,7,8,9-tetrahydro-2H-[1]benzofuro[3,2-g][1]benzopyran-2-one
35.7% inhibition at 0.01 mM
-
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
51.4% inhibition at 0.01 mM
-
3-(4-(4-(trifluoromethyl)benzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
3.86 % inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-bromobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
24.42% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-chlorobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
37.43% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-cyanobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
24.52% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
68.27% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-fluorobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
31.19% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
77.15% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
60.51% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
47.31% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-nitrobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
28.33% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
0.05% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(furan-2-carbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
9.44% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-benzoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
39.23% inhibition at 0.01 mM at pH 7.5, 25°C at pH 7.5, 25°C
-
3-(4-isonicotinoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
36.65% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-nicotinoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
30.95% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(benzo[d][1,3]dioxole-5-carbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
35.93% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
75.4% inhibition at 0.01 mM
-
3-tert-butyl-5,6-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
5.5% inhibition at 0.01 mM
-
3-[(3-oxobutan-2-yl)oxy]-6H-dibenzo[b,d]pyran-6-one
41.3% inhibition at 0.01 mM
-
3-[4-(furan-2-carbonyl)piperazin-1-yl]-N-(3-methylbut-2-en-1-yl)-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)propanamide
-
-
4-(1,3-dihydro-2H-isoindol-2-yl)benzaldehyde
-
-
4-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
27.23% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
33.01% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
13.10% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
32.19% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-biphenyl carboxylic acid
-
90% inhibition at 0.1 mM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
4-diethylaminobenzaldehyde
-
partial inhibition
4-dimethylamino-4-methyl-pent-2-ynthioic acid S-methyl ester
-
-
4-methyl-7-(2-oxo-2-phenylethoxy)-2H-1-benzopyran-2-one
71.0% inhibition at 0.01 mM
-
4-methyl-7-(2-oxopropoxy)-2H-1-benzopyran-2-one
47.8% inhibition at 0.01 mM
-
4-methyl-7-[(3-methylbut-2-en-1-yl)oxy]-2H-1-benzopyran-2-one
61.7% inhibition at 0.01 mM
-
4-methyl-7-[(prop-2-en-1-yl)oxy]-2H-1-benzopyran-2-one
64.5% inhibition at 0.01 mM
-
5-benzyl-2,3-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
43.0% inhibition at 0.01 mM
-
5-methyl-2-[(3-oxobutan-2-yl)oxy]-7H-furo[3,2-g][1]benzopyran-7-one
31.3% inhibition at 0.01 mM
-
6-benzyl-3,5-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
12.6% inhibition at 0.01 mM; 41.5% inhibition at 0.01 mM
-
6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
-
6-methyl-3,4-dihydro-2H,8H-benzo[1,2-b:5,4-b']dipyran-2,8-dione
34.8% inhibition at 0.01 mM
-
7-(2-oxopropoxy)-2H-1-benzopyran-2-one
7.6% inhibition at 0.01 mM
-
7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one
85.7% inhibition at 0.01 mM
-
7-methoxy-4-methyl-2H-1-benzopyran-2-one
19.8% inhibition at 0.01 mM
-
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
49.2% inhibition at 0.01 mM
-
8-[[4-(3-furoyl)-1-piperazinyl]methyl]-1,3-dimethyl-7-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione
i.e. CM026, 75.22% inhibition at 0.01 mM at pH 7.5, 25°C at pH 7.5, 25°C
-
9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
43.7% inhibition at 0.01 mM
-
9,10-dimethyl-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
17.6% inhibition at 0.01 mM
-
all-trans-retinal
-
9-cis-retinoic acid synthesis from 0.002 mM 9-cis-retinal is inhibited 50% by 0.005 mM all-trans-retinal
all-trans-retinol
-
competitive
alpha,alpha'-dipyridyl
-
slight
apo-CRBP
-
IC50 0.0014 mM
-
Atabrine
-
slight, FAD reverses inhibition
beta-ionone
potent inhibitor of isoform RALDH4 activity, at 0.002 mM concentration 9-cis and 13-cis retinal oxidation is reduced by 53% and 63%, respectively
Ca2+
-
50% inhibition at 0.22 mM
D-3,3',5-triiodothyronine
-
0.001 mM, 65% inhibition
dichloro-all-trans-retinone
-
diethylaminobenzaldehyde
DEAB, an ALDH1A1 inhibitor which competitively binds to the aldehyde-binding pocket of ALDH1A1 and completely inhibits the aldehyde oxidation activity of the enzyme at 0.01 mM, but has no effect on the GSH/DHLA-dependent NAD+-reduction activity
dimethyl ampal thiolester
-
estrogen
downregulates Raldh1 expression in the uterine glandular epithelium
ethanol
-
competitive inhibition
ethyl ([4-oxo-3-[3-(pyrrolidin-1-yl)propyl]-3,4-dihydro[1]benzothieno[3,2-d]pyrimidin-2-yl]sulfanyl)acetate
i.e. CM37
-
L-thyroxine
-
0.001 mM, 64% inhibition
Mn2+
-
50% inhibition at 0.024 mM
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
WIN 18,446; WIN 18,446, strong irreversible inhibition; WIN 18,446, weak inhibition
-
N,N'-octamethylenebis (dichloroacetamide)
-
complete inhibition at very low concentration below 1 pM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
N,N-diethylaminobenzaldehyde
-
N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3,5-dimethylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
6.25% inhibition at 0.01 mM at pH 7.5, 25°C
-
N-(3-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4,7-dimethyl-2-oxo-2H-1-benzopyran-6-yl)-2-methylpropanamide
40.2% inhibition at 0.01 mM
-
N-(4-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclobutylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclohexylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclopentylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclopropylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-benzyl-3-(2,3,5-trimethyl-7-oxo-7H-furo[3,2-g][1]benzopyran-6-yl)propanamide
6.4% inhibition at 0.01 mM
-
N-benzyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-butyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-ethyl-3-[4-(furan-2-carbonyl)piperazin-1-yl]-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)propanamide
-
-
N-ethyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isobutyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isopentyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isopropyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-propyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
NADPH
-
0.2 mM, 79% inhibition
nitrofen
-
90% inhibition at 0.1 mM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
p-chloromercuribenzoate
-
-
p-hydroxymercuribenzoate
-
complete inhibition at 1 mM in absence of DTT, 2 mM DTT protect nearly completely; strongly suppress enzyme reaction, reversed by addition of DTT
pravastatin sodium
-
cholesterol-lowering agent downregulates the expression of RALDH1,2 genes
retinol
-
40% uncompetitive inhibition of all-trans-retinal oxidation at 0.012 mM
SB-210661
-
80% inhibition at 1 mM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
Zn2+
-
50% inhibition at 0.01 mM
[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetonitrile
64.3% inhibition at 0.01 mM
-
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid
a 2,4-thiazolidinedione-3-acetic acid derivative
-
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
a 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivative; a 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivative and a non-competitive inhibitor of ALDH1A3
-
acetaldehyde
-
60% competitive inhibition of all-trans-retinal oxidation at 0.4 mM
acetaldehyde
-
0.2 mM, 0.5 mM and 1.0 mM, uncompetitive inhibition
Chloral hydrate
-
80% competitive inhibition of all-trans-retinal oxidation at 0.1 mM
Chloral hydrate
-
noncompetitive inhibition
citral
-
complete inhibition at 1 mM; strongly suppress enzyme reaction
citral
-
IC50 about 0.001 mM
dichloro-all-trans-retinone
irreversible inhibitor that effectively inhibits isoform RALDH1 in the nanomolar range. I.e. (3E,5E,7E,9E)-1,1-dichloro-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,5,7,9-tetraen-2-one; irreversible inhibitor that effectively inhibits isoforms RALDH2 in the nanomolar range. I.e. (3E,5E,7E,9E)-1,1-dichloro-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,5,7,9-tetraen-2-one; irreversible inhibitor that effectively inhibits isoforms RALDH3 in the nanomolar range. I.e. (3E,5E,7E,9E)-1,1-dichloro-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,5,7,9-tetraen-2-one
-
dichloro-all-trans-retinone
irreversible inhibitor that effectively inhibits isoform RALDH2 in the nanomolar range. I.e. (3E,5E,7E,9E)-1,1-dichloro-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,5,7,9-tetraen-2-one
-
Disulfiram
0.01 mM
Disulfiram
-
0.2 mM, 58% inhibition
Mg2+
at 30 mM Mg2+, significant inhibition of activity is shown for isoform RALDH1; at 30 mM Mg2+, significant inhibition of activity is shown for isoform RALDH2
Mg2+
inhibits the aldehyde dehydrogenase activity of ALDH1A1 by inhibiting the dissociation of NADH from the enzyme
Mg2+
-
about 50% inhibition of all-trans- and 9-cis-retinal oxidation above 1 mM
Mg2+
4 mM Mg2+ inhibits 9-cis retinal oxidation by isoform RALDH4 by 30%
Mg2+
specific activity is reduced half in presence of Mg2+
Mg2+
-
50% inhibition at 0.035 mM
N,N-diethylaminobenzaldehyde
DEAB; DEAB; DEAB
-
N,N-diethylaminobenzaldehyde
-
-
-
NaCN
-
slight
NADH
-
inhibits noncompetitively, inhibition not reversed by direct addition of NAD+
NADH
-
0.2 mM, 62% inhibition
retinal
-
strong substrate inhibition with 0.02 mM or more
retinal
-
substrate inhibition with concentration greater than 0.006 mM
WIN 18446
-
-
additional information
transfection of transcription factor cVax/Vax2 completely abolishes the spatial expression pattern of the retinoic acid synthesizing enzyme RALDH-1
-
additional information
transfection of transcription factor cVax/Vax2 completely abolishes the spatial expression pattern of the retinoic acid synthesizing enzyme RALDH-1
-
additional information
-
if dithiothreitol is omitted from the elution buffer during RDH13-His6 purification, the purified enzyme has a very low activity, but can be reactivated by the addition of dithiothreitol. Becomes partially inactivated after 20 min of incubation at 37°C. Not inhibited at 0.05 mM by nonanal, 6-cis-nonenal and 2-trans-nonenal, glyceraldehyde and acetoacetyl-coenzyme A, taurocholic acid, 25-hydroxycholesterol and 25-nor-5-cholesten-3-ol-25b-one
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. All tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1; design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. Almost all tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1; design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide effectively improves glucose consumption in Hep-G2 cells compared to compound 1 (CM026). Cell viability assays with compounds N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, and N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide in Hep-G2 cells. Comparison of inhibitory activities on different ALDH isozymes, overview
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. All tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1; design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. Almost all tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1; design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide effectively improves glucose consumption in Hep-G2 cells compared to compound 1 (CM026). Cell viability assays with compounds N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, and N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide in Hep-G2 cells. Comparison of inhibitory activities on different ALDH isozymes, overview
-
additional information
design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. All tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1; design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1, EC 1.2.1.36) inhibitors and comparison of inhibitory activities on different ALDH isozymes, overview. Almost all tested compounds exhibit almost no inhibition against isozyme ALDH1A2 and show excellent selectivity toward isozyme ALDH1A1; design and synthesis of 1,3-dimethylpyrimidine-2,4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide effectively improves glucose consumption in Hep-G2 cells compared to compound 1 (CM026). Cell viability assays with compounds N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide, and N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide in Hep-G2 cells. Comparison of inhibitory activities on different ALDH isozymes, overview
-
additional information
not inhibited by trans-anethole; not inhibited by trans-anethole; not inhibited by trans-anethole
-
additional information
not inhibited by trans-anethole; not inhibited by trans-anethole; not inhibited by trans-anethole
-
additional information
not inhibited by trans-anethole; not inhibited by trans-anethole; not inhibited by trans-anethole
-
additional information
-
not inhibited by trans-anethole; not inhibited by trans-anethole; not inhibited by trans-anethole
-
additional information
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid, a 2,4-thiazolidinedione-3-acetic acid derivative, is inactive as inhibitor; no inhibition of ALDH1A1 by [3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
additional information
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid, a 2,4-thiazolidinedione-3-acetic acid derivative, is inactive as inhibitor; no inhibition of ALDH1A1 by [3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
additional information
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid, a 2,4-thiazolidinedione-3-acetic acid derivative, is inactive as inhibitor; no inhibition of ALDH1A1 by [3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoic acid, 3-(7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-3-yl)propanoic acid, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one; inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one, and 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one; inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoic acid, 3-(7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-3-yl)propanoic acid, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one; inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one, and 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one; inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoic acid, 3-(7-hydroxy-4-methyl-2-oxo-2H-1-benzopyran-3-yl)propanoic acid, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one; inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by daidzin, methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one, and 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one; inhibition of the aldehyde dehydrogenase 1/2 family by psoralen and coumarin derivatives, structure-function relationships, overview. Poor or no inhibition by methyl 2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]propanoate, 7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one, and 6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
additional information
-
all-trans-retinol and chloral hydrate do not inhibit enzyme reaction
-
additional information
-
beta-ionone has no effect on isoform RALDH3 activity
-
additional information
beta-ionone has no effect on isoform RALDH3 activity
-